1. Scrip
  2. >>Business
  3. >>Deals

Deal-Making Attitudes Begin To Shift As Funding Options Decline

VC Investors Encourage Companies To Seek Partnerships

 
• By Mandy Jackson

An AbbVie executive at Biocom’s partnering conference said small firms are beginning to adjust their expectations due to financial market conditions; deal-makers noted biotechs should see value beyond cash in pharma collaborations.

Success in investing and earning concept. Dollar sign and financial report.
Deals are being considered over financings by some companies • Source: Alamy

Biotechnology company valuations have dropped significantly during the past year, but not yet to a level that has resulted in a lot of smaller firms selling themselves to big pharma. However, biotech companies are beginning to adjust their expectations in early deal negotiations as declining stock prices impact the number of financing options available to fund ongoing drug development programs, according to Jay Stamatis, vice president and head of business development and acquisitions at AbbVie Inc.

"It's a different time today than it was 12 months or nine months ago,” Stamatis said while speaking on a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

 
• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.

Deal Watch: Lilly Licenses Camurus’s Delivery Technology For Long-Acting Incretins

 
• By Joseph Haas

Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 
• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

More from Business

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.